Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.
Financial Results:
Supriya Lifescience Ltd reported Revenues for Q2FY24 of ₹140.00 Crores up from ₹112.00 Crore year on year, a rise of 25.0%.
Total Expenses for Q2FY24 of ₹112.00 Crores up from ₹88.00 Crores year on year, a rise of 27.27%.
Consolidated Net Profit of ₹24.00 Crores up 41.18% from ₹17.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹2.97, up 42.11% from ₹2.09 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.